Jakob Benedict Seidelin

Jakob Benedict Seidelin

Clinical Professor

Member of:

  • Internal Medicine: Gastroenterology and Hepatology

ORCID: 0000-0003-3230-7966

Publication year:
All
31 - 40 out of 117Page size: 10
  1. 2022
  2. Published

    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

    Peyrin-Biroulet, L., Hart, A., Bossuyt, P., Long, M., Allez, M., Juillerat, P., Armuzzi, A., Loftus, E. V., Ostad-Saffari, E., Scalori, A., Oh, Y. S., Tole, S., Chai, A., Pulley, J., Lacey, S., Sandborn, W. J., Aguilar, H., Ahmad, T., Akriviadis, E., Aldeguer Mante, X. & 31 others, Altorjay, I., Ananthakrishnan, A., Andersen, V., Andreu Garcia, M., Aumais, G., Avni-Biron, I., Axler, J., Ayub, K., Baert, F., Bafutto, M., Bamias, G., Bassan, I., Baum, C., Beaugerie, L., Behm, B., Bekal, P., Bennett, M., Bermejo San Jose, F., Bernstein, C., Bettenworth, D., Bhaskar, S., Biancone, L., Bilir, B., Blaeker, M., Bloom, S., Bohman, V., Bosques Padilla, F. J., Bouhnik, Y., Seidelin, Jakob Benedict, Staun, Michael & HICKORY Study Group, H. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 2, p. 128-140 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

    Vermeire, S. & LAUREL Study Group, L. S. G., 2022, In: The Lancet Gastroenterology and Hepatology. 7, 1, p. 28-37 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Zhao, M., Wewer, M. D., Bjerrum, Jakob Tveiten , Steenholdt, Casper, Schiødt, Frank Vinholt, Haderslev, K., Kiszka-Kanowitz, M., Munkholm, Pia, Seidelin, Jakob Benedict & Burisch, J., 2022, In: Ugeskrift for Laeger. 184, 11, V09210706.

    Research output: Contribution to journal › Review › Research › peer-review

  5. 2021
  6. Published

    Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study

    Albshesh, A., Taylor, J., Savarino, E. V., Truyens, M., Armuzzi, A., Ribaldone, D. G., Shitrit, A. B. G., Fibelman, M., Molander, P., Liefferinckx, C., Nancey, S., Korani, M., Rutka, M., Acosta, M. B. D., Domislovic, V., Suris, G., Eriksson, C., Alves, C., Mpitouli, A., Di Jiang, C. & 26 others, Tepeš, K., Coletta, M., Foteinogiannopoulou, K., Gisbert, J. P., Amir-Barak, H., Attauabi, M., Seidelin, Jakob Benedict, Afif, W., Marinelli, C., Lobaton, T., Pugliese, D., Maharshak, N., Cremer, A., Limdi, J. K., Molnár, T., Otero-Alvarin, B., Krznaric, Z., Magro, F., Karmiris, K., Raine, T., Drobne, D., Koutroubakis, I., Chaparro, M., Yanai, H., Burisch, J. & Kopylov, U., 2021, In: Journal of Clinical Medicine. 10, 13, 2914.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

    Attauabi, M. & Danish COVID-IBD Study Group, D. C. S. G., 2021, In: Gut. 70, 10, p. 2020-2022

    Research output: Contribution to journal › Letter › Research › peer-review

  8. Published

    Authors' Reply to: 'COVID-19 in the IBD Population: The Need for Correct Nomenclature'

    Attauabi, M., Seidelin, Jakob Benedict & Burisch, J., 22 Jun 2021, In: Journal of Crohn's & colitis. 15, 6, p. 1080 1 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  9. Published

    Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study

    Attauabi, M., Seidelin, Jakob Benedict, Felding, O. K., Wewer, M. D., Vinther Arp, L. K., Sarikaya, M. Z., Egeberg, A., Vladimirova, N., Bendtsen, Flemming & Burisch, J., Mar 2021, In: Journal of Autoimmunity. 118, 102613.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study

    Attauabi, M., Burisch, J. & Seidelin, Jakob Benedict, 2021, In: Inflammatory Bowel Diseases. 27, 3, p. e37-e38

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  11. Published

    Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature

    Attauabi, M., Burisch, J. & Seidelin, Jakob Benedict, 2021, In: Scandinavian Journal of Gastroenterology. 56, 1, p. 53-58 6 p.

    Research output: Contribution to journal › Review › Research › peer-review

  12. Published

    Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease: A Danish prospective population-based cohort study

    Attauabi, M., Poulsen, A., Theede, K., Pedersen, N., Larsen, L., Jess, T., Rosager Hansen, M., Kajbæk Verner-Andersen, M., V Haderslev, K., Berg Lødrup, A., Molazahi, A., Neumann, A., Wase, A., Seidelin, Jakob Benedict & Burisch, J., 2021, In: Journal of Crohn's and Colitis. 15, 4, p. 540–550

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 3 4 5 6 7 8 ...12 Next

ID: 33971112